China to soon launch Fruquintinib, its self-developed anti-cancer drug

Date: 2018-07-02   Author: Shikha Sinha  Category: #news

China to soon launch Fruquintinib, its self-developed anti-cancer drug

The China Food & Drug Administration has reportedly acknowledged an approval of the anti-cancer drug, Fruquintinib, for the treatment of patients with advanced colorectal cancer. Allegedly, the drug is likely to be approved by the year end and may hit the market soon.

According to reports, the anti-cancer drug is developed conjointly by Li Jin, an oncologist by profession & director of the Tumor Department at Shanghai East Hospital and Qin Shukui, associate head of the 81st PLA (People's Liberation Army) hospital and 28 domestic clinical drug research institutes.

According to the Journal of the American Medical Association (JAMA), the combined research by both the parties not only exhibited effective results in fighting colorectal cancer but also proved to be less toxic to humans.

Li revealed in a statement that the approval of the new drug will bring a ray of hope to the patients diagnosed with colorectal cancer and who have already undergone at least two chemotherapy treatment settings but are yet to see disease remission.

If reports are to be believed, the new drug could extend the life expectancy for over 9 months.

For the record, annually over 370,000 people are diagnosed with colorectal cancer in China and a majority of them are already in the last stages of the disease. Chemotherapy, in this regard is one of the most common treatment methods for colorectal cancer, however, it has shown very limited results on the late-stage patients.

Presently, China is the main producer of the generic anti-cancer drug, say sources familiar with the matter. The approval of the new drug Fruquintinib is set to hold importance as far as the country’s transition toward developing new drugs is concerned.

It has been reported that Shanghai East Hospital aims to develop minimum 30 new anticancer drugs every year and will be soon introducing 20 new clinical studies on anti-cancer drugs.



About Author


Shikha Sinha linkdin-boxtwitter

Shikha Sinha

Shikha currently manages the content team at AlgosOnline. An electrical & electronics engineer by education, she has prior experience in content & technology writing, content marketing, market research, and business development domains. Her other interests inc...

Read More

Post Recommendents

APAC, Europe, America region to materialize major revenue contributor for Non-invasive Ventilation Masks market through 2026

Author: Ashwin Naphade

The ' Non-invasive Ventilation Masks market' study Added by Market Study Report, LLC, delivers an in-depth outline regarding the powerful trends existing within the industry. The study also comprises significant information concerning grow...


Popularity of product to stimulate Aluminum Brazing Paste market outlook during 2021-2026

Author: Ashwin Naphade

Market Study Report, LLC, has added a research study on ' Aluminum Brazing Paste market' which offers a concise summary regarding market valuation, market share, regional spectrum, revenue estimation and SWOT analysis of this business vertical. Th...


Computerized Maintenance Management System (CMMS) Software market forecast unveils appealing opportunities over 2021-2026

Author: Ashwin Naphade

Market Study Report, LLC, has expanded its reports' database with a new research study on ' Computerized Maintenance Management System (CMMS) Software market' which features a precise summary of the business valuation, SWOT Analysis, market size, ...